ERBB2 and breast cancer: Among them, the distribution of HER2 status and molecular subtypes were representative of what is observed in the BC patient population at large (HER2 status: 6.6% equivocal, 26.7% positive and 66.7% negative; molecular subtypes: 6.7% HER2, 20.0% Luminal B, 10.0% TNBC and 63.3% Luminal A) [36].